{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:09:42Z","timestamp":1778962182975,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eimce.2026.503056","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:38:35Z","timestamp":1770309515000},"page":"503056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years"],"prefix":"10.1016","volume":"44","author":[{"given":"Concha","family":"Amador","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Mart\u00edn-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2026.503056_bib0315","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000001014","article-title":"Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimce.2026.503056_bib0320","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.eimce.2026.503056_bib0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eimce.2026.503056_bib0335","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.eimce.2026.503056_bib0340","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2026.503056_bib0345","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2026.503056_bib0350","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0355","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0360","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0365","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0370","series-title":"Biktarvy Summary of Product Characteristics","author":"European Medicines Agency (EMA)","year":"2018"},{"key":"10.1016\/j.eimce.2026.503056_bib0375","series-title":"U.S. FDA Approves Expanded Indication for Gilead's Biktarvy\u00ae","author":"Gilead sciences","year":"2024"},{"key":"10.1016\/j.eimce.2026.503056_bib0380","doi-asserted-by":"crossref","DOI":"10.1177\/13596535231159030","article-title":"Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review","volume":"28","author":"Peters","year":"2023","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimce.2026.503056_bib0385","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hiv.13593","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts","volume":"25","author":"Esser","year":"2024","journal-title":"HIV Med"},{"key":"10.1016\/j.eimce.2026.503056_bib0390","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/POR.S396024","article-title":"Tactical considerations for designing real-world studies: fit-for-purpose designs that bridge research and practice","volume":"14","author":"Dreyer","year":"2023","journal-title":"Pragmatic Obs Res"},{"key":"10.1016\/j.eimce.2026.503056_bib0395","series-title":"UNAIDS Country Factsheet: Spain","author":"UNAIDS","year":"2023"},{"key":"10.1016\/j.eimce.2026.503056_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.eimce.2026.503056_bib0405","doi-asserted-by":"crossref","first-page":"107164","DOI":"10.1016\/j.ijantimicag.2024.107164","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial","volume":"63","author":"Hidalgo Tenorio","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2026.503056_bib0410","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in a multicentre cohort: real-life experience from Spain","author":"Torralba","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimce.2026.503056_bib0415","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107016","article-title":"Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV late presenters","volume":"63","author":"Corona","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2026.503056_bib0425","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice","volume":"78","author":"Su\u00e1rez-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0430","first-page":"S46","article-title":"Estudio BIFAST: resultados a 48 semanas del uso de PROs en el inicio r\u00e1pido del TAR con B\/F\/TAF en PVIH na\u00efves","volume":"41","author":"Al-Hayani","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2026.503056_bib0435","first-page":"S44","article-title":"Eficacia de Biktarvy\u00ae BIC\/TAF\/FTC como tratamiento de inicio en personas con infecci\u00f3n VIH en pr\u00e1ctica cl\u00ednica","volume":"41","author":"Savorido Alconchel","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2026.503056_bib0440","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s41669-022-00322-w","article-title":"Epidemiologic and economic analysis of rapid antiretroviral therapy initiation with bictegravir\/emtricitabine\/tenofovir alafenamide in Spain","volume":"6","author":"Estrada","year":"2022","journal-title":"PharmacoEconomics \u2013 Open"},{"key":"10.1016\/j.eimce.2026.503056_bib0445","doi-asserted-by":"crossref","first-page":"e1991","DOI":"10.1093\/cid\/ciaa1416","article-title":"Dynamics of the decay of human immunodeficiency virus (HIV) RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naive adults living with HIV-1 treated with bictegravir\/emtricitabine\/tenofovir alafenamide (Spanish HIV\/AIDS)","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503056_bib0450","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in mediterranean Europe","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503056_bib0455","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503056_bib0460","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0465","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2026.503056_bib0470","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2026.503056_bib0475","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2026.503056_bib0480","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jac\/dkae011","article-title":"Real-life data of immune recovery using bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study","volume":"79","author":"Troya","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0485","article-title":"Comparative observational study of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide versus bictegravir\/emtricitabine\/tenofovir alafenamide in high-risk non-adherent people living with HIV","author":"Knobel","year":"2023","journal-title":"19th Eur AIDS Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0490","article-title":"Bikswitch study: Effectiveness and safety of switching to a bictegravir-based antiretroviral therapy regimen from non-integrase inhibitor-based therapies in virologically suppressed HIV-infected patients","author":"Perez","year":"2023","journal-title":"19th Eur AIDS Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0495","first-page":"S45","article-title":"Eficacia inmunovirol\u00f3gica y tolerabilidad de TAR basado en doravirina: an\u00e1lisis comparativo vs. BIC\/FTC\/TAF a 48 semanas en pr\u00e1ctica cl\u00ednica","volume":"41","author":"Mart\u00ednez Vera","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2026.503056_bib0500","article-title":"Real-life data of bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed women with VIH-1","author":"Pousada","year":"2023","journal-title":"19th Eur AIDS Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0505","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/jac\/dkae138","article-title":"Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis","volume":"79","author":"Chivite","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0510","first-page":"S41","article-title":"BIC\/FTC\/TAF in PLWV with persistent low-level viremia: 48\u201396 weeks results of RETROBIC cohort study","volume":"41","author":"Santos","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2026.503056_bib0515","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/jac\/dkad285","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) plus darunavir\/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens","volume":"78","author":"Podzamczer","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0520","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-5","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","volume":"12","author":"Ryan","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2026.503056_bib0525","article-title":"Switching to dolutegravir\/lamivudine or bictegravir\/emtricitabine\/tenofovir alafenamide. A comparative real-world study","volume":"24","author":"Knobel","year":"2023","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.eimce.2026.503056_bib0530","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1093\/jac\/dkad338","article-title":"Tolerability of bictegravir\/tenofovir alafenamide\/emtricitabine versus dolutegravir\/lamivudine as maintenance therapy in a real-life setting","volume":"78","author":"Rocabert","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503056_bib0535","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"P\u00e9rez-Valero","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.eimce.2026.503056_bib0540","article-title":"Differences in bictegravir safety and tolerance in naive versus antiretroviral experienced patients in real life","author":"Velasco","year":"2023","journal-title":"ECCMID"},{"key":"10.1016\/j.eimce.2026.503056_bib0545","article-title":"Metabolic effects of switching to tenofovir alafenamide\/emtricitabine\/bictegravir (B\/F\/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study","volume":"25","author":"Busca","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eimce.2026.503056_bib0550","article-title":"Weight and Body Mass Index gain among people living with HIV-1 switching to a single tablet of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF)","author":"Buz\u00f3n","year":"2023","journal-title":"19th Eur AIDS Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0555","first-page":"S52","article-title":"Real-world effectiveness, safety and patient-reported outcomes (PROs) of bictegravir\/emtricitabine\/tenofovir alafenamide (b\/f\/taf) in people with HIV (PWH): 24-month (24m) outcomes from the Spanish cohort of BICSTAR","volume":"41","author":"Mayorga","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2026.503056_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106493","article-title":"Management of comorbidities in treated HIV infection: a long way to go: HIV, comorbidities and aging","volume":"59","author":"Mart\u00ednez-Sanz","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2026.503056_bib0565","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3390\/v15051097","article-title":"HIV and co-infections: updates and insights","volume":"15","author":"Di Gennaro","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.eimce.2026.503056_bib0570","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1192\/apt.bp.116.016311","article-title":"HIV infection and its psychiatric manifestations: a clinical overview","volume":"23","author":"Chatziagorakis","year":"2017","journal-title":"BJPsych Adv"},{"key":"10.1016\/j.eimce.2026.503056_bib0575","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001441","article-title":"Pharmacotherapeutic interventions in people living with HIV undergoing solid organ transplantation: a scoping review","volume":"9","author":"Lam","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.eimce.2026.503056_bib0580","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa625","article-title":"Incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-experienced patients","volume":"8","author":"Schafer","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eimce.2026.503056_bib0585","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.eimce.2026.503056_bib0590","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/1570162X20666220608160335","article-title":"Short-term neuropsychiatric and body weight changes in patients switching from EVG\/Cobi\/FTC\/TAF to BIC\/FTC\/TAF (PreEC\/RIS69)","volume":"20","author":"Tiraboschi","year":"2022","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.eimce.2026.503056_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120948","article-title":"Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes","volume":"308","author":"Domingo","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.eimce.2026.503056_bib0600","article-title":"Impact of switching from dual to triple therapy on inflammation: INSTINCT study","volume":"2024","author":"Serrano-Villar","year":"2024","journal-title":"CROI Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0605","doi-asserted-by":"crossref","first-page":"848630","DOI":"10.3389\/fimmu.2022.848630","article-title":"Long-term changes of inflammatory biomarkers in individuals on suppressive three-drug or two-drug antiretroviral regimens","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eimce.2026.503056_bib0610","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/infdis\/jiz624","article-title":"Total and unbound bictegravir concentrations and viral suppression in cerebrospinal fluid of human immunodeficiency virus-infected patients (Spanish HIV\/AIDS Research Network, PreEC\/RIS 56)","volume":"221","author":"Tiraboschi","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503056_bib0615","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-experienced people with HIV (PWH) with baseline symptoms of depression\/anxiety and\/or insomnia in the observational BICSTaR study","author":"Esser","year":"2023","journal-title":"19th Eur AIDS Conf"},{"key":"10.1016\/j.eimce.2026.503056_bib0620","first-page":"231","article-title":"Optimizing antiretroviral therapy with bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed PLWH","volume":"46","author":"Andreoni","year":"2023","journal-title":"New Microbiol"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:50:40Z","timestamp":1778961040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X26000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2529993X26000109"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503056","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bictegravir\/emtricitabine\/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica.","name":"copyright","label":"Copyright"}],"article-number":"503056"}}